INF904 advances in ANCA-associated vasculitis with Phase II trials planned
核心洞察
InflaRx is prioritizing ANCA vasculitis (搜索) in a strategic pivot, with INF904 designed for improved safety and efficacy, according to its Cantor Fitzgerald Global Healthcare Conference presentation.
Vilobelimab is positioned as a bridging option for the company amid competitor withdrawals from the space.
Phase II trials for INF904 are set to begin early next year, with regulatory engagement active and broader renal indications under consideration.
InflaRx N.V. (搜索) is making ANCA vasculitis (搜索) its lead focus under a strategic pivot, advancing INF904 as a candidate designed for better safety and efficacy. The company presented the plan at the 12th Annual Cantor Fitzgerald Global Healthcare Conference.
Vilobelimab is being kept as a bridging option amid competitor withdrawals from the indication. Regulatory engagement on the program is active, and phase II trials are set to begin early next year, with broader renal indications also under consideration.